See CJC-1295 DAC/Ipamorelin blend dosage trends, reconstitution volumes, and vial size patterns from WPA peptide calculator sessions.
The CJC-1295 DAC/Ipamorelin blend pairs a long-acting GHRH analog (drug affinity complex form) with a selective GHRP, allowing for less frequent dosing versus the non-DAC variant. This data shows the dose amounts, vial sizes, and bacteriostatic water volumes researchers most commonly select when reconstituting this GH-stimulating peptide combination.
The CJC-1295 DAC/Ipamorelin blend is the long-acting cousin of the more popular No DAC blend on this site, and the single fact that defines it is the drug-affinity-complex (DAC) linker on the GHRH side. , Journal of Clinical Endocrinology & Metabolism 2006 ("Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults") characterized the DAC variant as producing sustained IGF-1 elevation for up to 28 days after a single subcutaneous dose, with a half-life on the order of 5-8 days — fundamentally different from the ~30-minute half-life of CJC-1295 No DAC (Modified GRF 1-29).
This blend combines CJC-1295 with the Drug Affinity Complex (DAC) — a maleimide-propionic-acid linker that covalently tethers the GHRH(1-29) analog to circulating serum albumin — with the selective ghrelin-receptor (GHS-R1a) agonist ipamorelin. The DAC modification, originally developed by ConjuChem, extends CJC-1295's half-life from minutes to roughly 8 days.
CJC-1295 with DAC produces continuous, albumin-mediated GHRH-receptor activation rather than the pulsatile signal seen with the no-DAC variant — boosting baseline IGF-1 substantially but partially abolishing the body's endogenous GH pulse pattern. Adding ipamorelin recruits the parallel GHS-R1a pathway, which appears in pre-clinical work to partially restore a pulsatile pattern on top of the elevated baseline.
No published trial evaluates the DAC/ipamorelin fixed-ratio blend in humans. Evidence is limited to the individual molecules: Teichman et al. (JCEM 2006) characterized CJC-1295's prolonged action in healthy adults, and Raun et al. (Eur J Endocrinol 1998) established ipamorelin's GH-selectivity over ACTH and prolactin. The blend differs clinically from the more widely studied no-DAC/ipamorelin combination by producing far higher baseline IGF-1 elevation.
CJC-1295 DAC/Ipamorelin Blend has a reported half-life of ~6–8 days (CJC-DAC-driven), and the dose intervals researchers model most often fall around once or twice weekly. The CJC-1295 DAC component lasts about a week and builds up over several weeks, while the ipamorelin clears within hours and acts as a short pulse each dose. CJC-1295 DAC/Ipamorelin Blend is a blend of CJC-1295 DAC and Ipamorelin, so a reconstitution figure for it covers the combined vial contents rather than any single component. It is catalogued under Muscle Peptides on WPA.
315 CJC-1295 DAC/Ipamorelin Blend reconstitution calculations have been logged by the WPA community. The most common dose entered is 250mcg (58 calculations). The median dose across all sessions is 300mcg. The most common bacteriostatic water volume is 2mL. The most popular vial size is 10mg (221 sessions). The most common dosing frequency is daily (7x/week) (32 logged protocols), followed by 2x/week (28).
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.